Corbus Pharmaceuticals Announced Saturday, SYS6002 (CRB-701) Continues to Demonstrate Safety And Efficacy In Nectin-4 Positive Tumors, ASCO 2024 Clinical Update Reveals
Portfolio Pulse from Benzinga Newsdesk
Corbus Pharmaceuticals announced that their drug SYS6002 (CRB-701) continues to show safety and efficacy in treating Nectin-4 positive tumors, according to an ASCO 2024 clinical update. The drug demonstrated significant ORR and DCR in both mUC and cervical cancer patients, with no dose-limiting toxicities observed up to 4.5 mg/Kg.
June 03, 2024 | 7:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corbus Pharmaceuticals' SYS6002 (CRB-701) continues to demonstrate safety and efficacy in Nectin-4 positive tumors, with significant ORR and DCR in mUC and cervical cancer patients. No dose-limiting toxicities have been observed up to 4.5 mg/Kg.
The positive clinical update on SYS6002 (CRB-701) is likely to boost investor confidence in Corbus Pharmaceuticals. The significant ORR and DCR in mUC and cervical cancer, along with the absence of dose-limiting toxicities, suggest strong potential for the drug, which could positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100